Log in

Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

$18.86
-0.04 (-0.21 %)
(As of 10/20/2019 09:32 AM ET)
Today's Range
$18.69
Now: $18.86
$19.07
50-Day Range
$18.40
MA: $22.37
$26.79
52-Week Range
$12.59
Now: $18.86
$29.80
Volume181,650 shs
Average Volume587,300 shs
Market Capitalization$732.15 million
P/E Ratio20.06
Dividend YieldN/A
Beta1.51
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$343.37 million
Cash Flow$1.36 per share
Book Value$1.85 per share

Profitability

Net Income$40.51 million

Miscellaneous

Employees488
Market Cap$732.15 million
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.


Lantheus (NASDAQ:LNTH) Frequently Asked Questions

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

How were Lantheus' earnings last quarter?

Lantheus Holdings Inc (NASDAQ:LNTH) announced its earnings results on Thursday, July, 25th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.27. The medical equipment provider had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The business's revenue was up .1% on a year-over-year basis. During the same quarter last year, the firm posted $0.25 EPS. View Lantheus' Earnings History.

When is Lantheus' next earnings date?

Lantheus is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Lantheus.

How can I listen to Lantheus' earnings call?

Lantheus will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share guidance of $1.09-1.12 for the period, compared to the Thomson Reuters consensus estimate of $1.12. The company issued revenue guidance of $346-350 million, compared to the consensus revenue estimate of $360.07 million.

What is the consensus analysts' recommendation for Lantheus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Has Lantheus been receiving favorable news coverage?

Headlines about LNTH stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lantheus earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Lantheus.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,410,000 shares, an increase of 6.8% from the August 30th total of 1,320,000 shares. Based on an average daily volume of 432,500 shares, the short-interest ratio is currently 3.3 days. Currently, 3.7% of the shares of the company are short sold. View Lantheus' Current Options Chain.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

Who are Lantheus' key executives?

Lantheus' management team includes the folowing people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
  • Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
  • Mr. John J. Bolla, Chief Operating Officer (Age 49)

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.56%), Bowling Portfolio Management LLC (0.11%), State of Alaska Department of Revenue (0.08%), Envestnet Asset Management Inc. (0.06%) and Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Campbell & CO Investment Adviser LLC and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

Which major investors are buying Lantheus stock?

LNTH stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Envestnet Asset Management Inc.. View Insider Buying and Selling for Lantheus.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $18.86.

How big of a company is Lantheus?

Lantheus has a market capitalization of $732.15 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

What is Lantheus' official website?

The official website for Lantheus is http://www.lantheus.com/.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]


MarketBeat Community Rating for Lantheus (NASDAQ LNTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  250 (Thanks for Voting!)
Underperform Votes:  230 (Thanks for Voting!)
Total Votes:  480
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel